Clinical studies on claudin-18.2 for GC have achieved promising results, and the development of claudin-18.2 and claudin-4-targeted drugs and combination therapies for PCa are also expected to provide promising results in PCa diagnosis and treatment. Here, CLDN4 is linked to posterior cortical atrophy.